Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds

Core Viewpoint - Vivos Therapeutics, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $4.64 million to support its operations in the sleep-related breathing disorder market, particularly obstructive sleep apnea (OSA) [1][4]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues, particularly OSA and snoring [7]. - The company’s devices have received FDA clearance for treating OSA in adults and children aged 6 to 17, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. Market Context - OSA affects over 1 billion people globally, with 90% remaining undiagnosed, highlighting a significant market opportunity for innovative treatments [8]. - Traditional treatments like CPAP often fail to address the root causes of OSA, indicating a need for more effective solutions [8]. Financial Activity - The company exercised warrants to purchase up to 1,982,356 shares at a reduced price of $2.34 per share, originally priced between $3.83 and $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. Use of Proceeds - The net proceeds from the warrant exercise will be utilized for working capital and general corporate purposes [4].